Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 11, 2002, Pages 625-632

  Soiffer, Robert J ^a   Alyea, Edwin P ^a   Hochberg, Ephraim ^a   Wu, Catherine ^a   Canning, Christine ^a   Parikh, Bijal ^a   Zahrieh, David ^a   Webb, Iain ^a   Antin, Joseph ^a   Ritz, Jerome ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CD8+ T cell depletion; Donor lymphocyte infusion; Graft versus host disease

Indexed keywords

ACICLOVIR; CD8 ANTIGEN; COMPLEMENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; CHIMERA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; CYTOGENETICS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INCIDENCE; INFUSION; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; REVIEW; T LYMPHOCYTE;

EID: 6444245796     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.abbmt080625     Document Type: Article

References (45)

1. Kolb H, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
2. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-vs-host disease as immunotherapy for relapsed chronic myelogenous leukemia. N Engl J Med. 1994;330:100-106.
3. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310-2318.
4. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
5. Collins R, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
6. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87: 1196-1198.
7. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91: 3671-3680.
8. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
9. Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000;6:375-386.
10. Wu CJ, Chillemi A, Alyea EP, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95:352-359.
11. Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98:934-939.
12. Barrett AJ, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 1998;21:543-551.
13. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
14. Martino R, Martin-Henao G, Sureda A, et al. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults: results of a single center pilot study. Haematologica. 2000;85:1165-1171.
15. Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561-568.
16. Porter DL, Antin JH. Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998;12: 123-150.
17. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
18. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95:67-71.
19. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86: 4337-4343.
20. Champlin R, Ho W, Gajewski J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990;76:418-423.
21. Soiffer RJ, Gonin R, Murray C, et al. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood. 1993;82:2216-2223.
22. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992;10:1191-2000.
23. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15: 825-828.
24. Hochberg EP, Chillemi AC, Wu CJ, et al. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001;98:1116-1121.
25. Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997;100:855-866.
26. Kaplan G, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
27. Mehta C, Patel N. A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables. J Am Stat Assoc. 1983;78:427-434.
28. Soiffer RJ, Bosserman L, Murray C, Cochran K, Daley J, Ritz J. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990;75:2076-2084.
29. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000;106:705-714.
30. Kong FK, Chen CL, Six A, Hockett RD, Cooper MD. T cell receptor gene deletion circles identify recent thymic emigrants in the peripheral T cell pool. Proc Natl Acad Sci U S A. 1999;96:1536-1540.
31. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-695.
32. Zhang L, Lewin SR, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med. 1999;190:725-732.
33. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
34. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63-72.
35. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94: 1201-1208.
36. Zorn E, Orsini E, Wu CJ, et al. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001;71:1131-1137.
37. Mackinnon S, Barnett L, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:3409-3416.
38. Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation. 1994;57:82-87.
39. Martin PJ, Rowley SD, Anasetti C, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood. 1999;94:2192-2199.
40. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175-181.
41. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685-3691.
42. Korngold R, Sprent J. Murine models for graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell Science; 1999:296-304.
43. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen presenting cells. Science. 1999;285:412-415.
44. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-versus-host disease [review]. Biol Blood Marrow Transplant. 1999;5:347-356.
45. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff JJ, eds. Graft-vs-Host Disease. 2nd ed. New York: Marcel Dekker; 1997:257-290.